Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors

被引:65
作者
de Raaf, Pleun J. [1 ]
Sleijfer, Stefan
Lamers, Cor H. J. [1 ]
Jager, Agnes
Gratama, Jan Willem [1 ]
van der Rijt, Carin C. D.
机构
[1] Dr Daniel Den Hoed Canc Ctr, Erasmus MC, Dept Med Oncol, Lab Clin Tumor Immunol, NL-3008 AE Rotterdam, Netherlands
关键词
neoplasms; fatigue; mental fatigue; survivors; palliative care; C-reactive protein; interleukin-6; interleukin-8; interleukin-1 receptor antagonist protein; neopterin; DISEASE; INTERLEUKIN-1; MECHANISMS; DEPRESSION; CYTOKINES; INVENTORY; SYMPTOMS; RHYTHM; SLEEP;
D O I
10.1002/cncr.27613
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
BACKGROUND: Inflammation may underlie cancer-related fatigue; however, there are no studies that assess the relation between fatigue and cytokines in patients with advanced disease versus patients without disease activity. Furthermore, the relation between cytokines and the separate dimensions of fatigue is unknown. Here, association of plasma levels of inflammatory markers with physical fatigue and mental fatigue was explored in advanced cancer patients and cancer survivors. METHODS: A total of 45 advanced cancer patients and 47 cancer survivors completed the subscales Physical Fatigue and Mental Fatigue of the Multidimensional Fatigue Inventory. Plasma concentrations of C-reactive protein (CRP), interleukin-1 receptor antagonist (IL-1-ra), interleukin-6 (IL-6), interleukin-8 (IL-8), and neopterin were measured. Nonparametric tests were used to assess differences in fatigue intensity and levels of inflammatory markers and to determine correlation coefficients between the fatigue dimensions and inflammatory markers. RESULTS: Compared with cancer survivors, patients with advanced cancer had higher levels of physical fatigue (median 16 vs 9, P < .001) and mental fatigue (median 11 vs 6, P = .01). They also had higher levels of all cytokines (P < .01). In advanced cancer, CRP (r = 0.49, P = .001), IL-6 (r = 0.43, P = .003), IL-1-ra (r = 0.32, P = .03), and neopterin (r = 0.25, P = .10) were correlated with physical but not with mental fatigue. In cancer survivors, only IL-1-ra was related to both physical fatigue (r = 0.24, P = .10) and mental fatigue (r = 0.35, P = .02). CONCLUSIONS: In advanced cancer, inflammation seems to be associated with physical fatigue, but not to mental fatigue. In cancer survivors, there was no convincing evidence that inflammation plays a major role in fatigue. Cancer 2012. (c) 2012 American Cancer Society.
引用
收藏
页码:6005 / 6011
页数:7
相关论文
共 30 条
[1]
A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer [J].
Bayliss, Trevor J. ;
Smith, Jeff T. ;
Schuster, Michael ;
Dragnev, Konstantin H. ;
Rigas, James R. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (12) :1663-1668
[2]
Fatigue and proinflammatory cytokine activity in breast cancer survivors [J].
Bower, JE ;
Ganz, PA ;
Aziz, N ;
Fahey, JL .
PSYCHOSOMATIC MEDICINE, 2002, 64 (04) :604-611
[3]
Inflammation and Behavioral Symptoms After Breast Cancer Treatment: Do Fatigue, Depression, and Sleep Disturbance Share a Common Underlying Mechanism? [J].
Bower, Julienne E. ;
Ganz, Patricia A. ;
Irwin, Michael R. ;
Kwan, Lorna ;
Breen, Elizabeth C. ;
Cole, Steve W. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) :3517-3522
[4]
Inflammatory biomarkers for persistent fatigue in breast cancer survivors [J].
Collado-Hidalgo, A ;
Bower, JE ;
Ganz, PA ;
Cole, SW ;
Irwin, MR .
CLINICAL CANCER RESEARCH, 2006, 12 (09) :2759-2766
[5]
Differences in Fatigue Experiences Among Patients With Advanced Cancer, Cancer Survivors, and the General Population [J].
de Raaf, Pleun J. ;
de Klerk, Cora ;
Timman, Reinier ;
Hinz, Andreas ;
van der Rijt, Carin C. D. .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2012, 44 (06) :823-830
[6]
Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment [J].
Dimeo, F ;
Schmittel, A ;
Fietz, T ;
Schwartz, S ;
Köhler, P ;
Böning, D ;
Thiel, E .
ANNALS OF ONCOLOGY, 2004, 15 (08) :1237-1242
[7]
Biologic basis for interleukin-1 in disease [J].
Dinarello, CA .
BLOOD, 1996, 87 (06) :2095-2147
[8]
Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) [J].
El-Osta, Hazem ;
Janku, Filip ;
Kurzrock, Razelle .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (06) :1485-1488
[9]
Mechanisms of disease: Acute-phase proteins and other systemic responses to inflammation [J].
Gabay, C ;
Kushner, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (06) :448-454
[10]
Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein [J].
Gabay, C ;
Smith, MF ;
Eidlen, D ;
Arend, WP .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (12) :2930-2940